Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Ruff

Showing results (31-40 of 93) with videos related to

Pageof 10
Sort By:
JCO Global Oncology|June 18, 2025
Establishing Requirements for Breast Centers in Low- and Middle-Income Countries: A South African PerspectiveSarah Nietz, Jenny Edge, Ines Buccimazza, et al.
BMC Cancer|July 20, 2004
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancerThomas Kuehr, Paul Ruff, Bernardo L Rapoport, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2018
Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT StudyMarc Peeters, Timothy Price, Michael Boedigheimer, et al.
European Journal of Cancer (Oxford, England : 1990)|October 8, 2016
Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancerTimothy Price, Tae Won Kim, Jin Li, et al.
Breast (Edinburgh, Scotland)|December 15, 2018
Clinico-pathological characteristics among South African women with breast cancer receiving anti-retroviral therapy for HIVBoitumelo Phakathi, Herbert Cubasch, Sarah Nietz, et al.
BMC Infectious Diseases|September 16, 2003
Risk factors for high anti-HHV-8 antibody titers (> or =1:51,200) in black, HIV-1 negative South African cancer patients: a case control studyJanet M Wojcicki, Rob Newton, Margaret I Urban, et al.
Plos One|February 3, 2018
Barriers to early presentation of breast cancer among women in Soweto, South AfricaMaureen Joffe, Oluwatosin Ayeni, Shane Anthony Norris, et al.
Breast (Edinburgh, Scotland)|June 14, 2021
Survival of south african women with breast cancer receiving anti-retroviral therapy for HIVBoitumelo Phakathi, Sarah Nietz, Herbert Cubasch, et al.
Cancers|July 2, 2020
Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510GHiroya Taniguchi, Takeharu Yamanaka, Daisuke Sakai, et al.
ESMO Open|November 16, 2016
Quality of life during first-line FOLFOX4±panitumumab in <i>RAS</i> wild-type metastatic colorectal carcinoma: results from a randomised controlled trialSalvatore Siena, Josep Tabernero, Gyorgy Bodoky, et al.
Pageof 10

Showing results (31-40 of 93) with videos related to

Sort By:
Pageof 10
JCO Global Oncology|June 18, 2025
Establishing Requirements for Breast Centers in Low- and Middle-Income Countries: A South African PerspectiveSarah Nietz, Jenny Edge, Ines Buccimazza, et al.
BMC Cancer|July 20, 2004
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancerThomas Kuehr, Paul Ruff, Bernardo L Rapoport, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2018
Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT StudyMarc Peeters, Timothy Price, Michael Boedigheimer, et al.
European Journal of Cancer (Oxford, England : 1990)|October 8, 2016
Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancerTimothy Price, Tae Won Kim, Jin Li, et al.
Breast (Edinburgh, Scotland)|December 15, 2018
Clinico-pathological characteristics among South African women with breast cancer receiving anti-retroviral therapy for HIVBoitumelo Phakathi, Herbert Cubasch, Sarah Nietz, et al.
BMC Infectious Diseases|September 16, 2003
Risk factors for high anti-HHV-8 antibody titers (> or =1:51,200) in black, HIV-1 negative South African cancer patients: a case control studyJanet M Wojcicki, Rob Newton, Margaret I Urban, et al.
Plos One|February 3, 2018
Barriers to early presentation of breast cancer among women in Soweto, South AfricaMaureen Joffe, Oluwatosin Ayeni, Shane Anthony Norris, et al.
Breast (Edinburgh, Scotland)|June 14, 2021
Survival of south african women with breast cancer receiving anti-retroviral therapy for HIVBoitumelo Phakathi, Sarah Nietz, Herbert Cubasch, et al.
Cancers|July 2, 2020
Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510GHiroya Taniguchi, Takeharu Yamanaka, Daisuke Sakai, et al.
ESMO Open|November 16, 2016
Quality of life during first-line FOLFOX4±panitumumab in <i>RAS</i> wild-type metastatic colorectal carcinoma: results from a randomised controlled trialSalvatore Siena, Josep Tabernero, Gyorgy Bodoky, et al.
Pageof 10